Action PRME PRIME MEDICINE, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Prime Medicine, Inc.

Actions

PRME

US74168J1016

Marché Fermé - Nasdaq
Autres places de cotation
 22:00:00 20/05/2024 		Varia. 5j. Varia. 1 janv.
7,53 USD +6,36% Graphique intraday de Prime Medicine, Inc. +17,29% -15,01%
20/05 PRIME MEDICINE, INC. : HC Wainwright favorable au dossier ZM
16/05 PRIME MEDICINE, INC. : Citigroup adopte une opinion positive ZM

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
North American Morning Briefing : The "Everything -2-
Prime medicine reports first quarter 2024 financial results and provides business updates
Prime Medicine to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
Prime Medicine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Earnings Flash (PRME) PRIME MEDICINE Reports Q1 Revenue $591,000
Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates
Prime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Granulomatous Disease (CGD)
Prime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Granulomatous Disease (CGD)
Prime Medicine to Participate in the 27th Annual Milken Institute Global Conference
Prime Medicine Shares Jump After Application for Chronic Granulomatous Disease Treatment Gets FDA Clearance
Prime Medicine Gets FDA Clearance for PM359 IND Application
Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)
Prime Medicine Announces FDA Clearance of Investigational New Drug Application for PM359 for the Treatment of Chronic Granulomatous Disease
Prime Medicine to Present Preclinical Data Demonstrating Broad Potential of Prime Editing Technology at Upcoming Scientific Meetings
Prime Medicine to Present Preclinical Data Demonstrating Broad Potential of Prime Editing Technology at Upcoming Scientific Meetings
Prime medicine reports full year 2023 financial results and provides business updates
Prime Medicine 2023 Net Loss Narrows
Prime Medicine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates
Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action PRME
  4. Actualités Prime Medicine, Inc.
  5. Autres langues
-40% Offre à Durée Limitée : Nos abonnements vous guident vers les meilleurs investissements de demain.
PROFITEZ-EN MAINTENANT